With just a few hours left before the end of trade on Friday, the S&P/ASX 200 Index (ASX: XJO) is up 3.1% for the week, with these three ASX 200 stocks racing ahead of those gains.
Here's what's been piquing investor interest this week.
Image source: Getty Images
Westgold Resources Ltd (ASX: WGX)
At time of writing Westgold shares are changing hands for $5.59 apiece, putting this ASX 200 stock up 18.2% for the week.
The Aussie gold miner got a big boost on Wednesday, after announcing it was increasing the processing capacity at its Western Australian Cue processing hub from 1.4 million tonnes per annum (Mtpa) to 1.7 Mtpa by FY 2028, representing a 21% boost.
The miner expects this will enable it to increase gold production by some 15,000 ounces per year.
"Bigger mines need bigger mills," Westgold CEO Wayne Bramwell said.
He added:
This simple upgrade and modest capital investment at the Cue hub reflects a deliberate shift towards processing hub optimisation and expansion, with lower operating costs and higher cashflow the objective.
Pinnacle Investment Management Group Ltd (ASX: PNI)
The second ASX 200 stock storming higher on big news this week is financial services company Pinnacle Investment.
Pinnacle shares are currently trading for $18.74 each, up 17.3% since last Friday's close.
Investors bid up the Pinnacle share price following on the company's full year FY 2026 results release on Tuesday.
Highlights included a 28% year on year increase in aggregate funds under management (FUM) to $229.4 billion. That was supported by record net inflows of $33.4 billion, including retail and international inflows.
On the bottom line, Pinnacle shares got caught tailwinds with the company reporting FY 2026 underlying net profit after tax (NPAT) of $138.0 million, up 21%.
Commenting on the results, Pinnacle CEO Ian Macoun said:
We continue to build Pinnacle to deliver sustained high rates of growth for many years into the future. Our distinct business model and Three Horizons growth strategy have built a highly diversified platform across asset classes, geographies and product formats.
Which brings us to…
Neuren Pharmaceuticals Ltd (ASX: NEU)
Neuren shares are currently trading at $22.39, which sees this ASX 200 stock up an impressive 24.2% for the week.
Shares in the ASX 200 biopharmaceutical company closed up 16.3% on Wednesday following the release of Neuren's second quarter (Q2 2026) update.
Investors were piling into the stock, with Neuren reporting a 24% quarter-on-quarter increase in net sales from its patented prescription drug DAYBUE to US$125 million.
This saw full calendar year 2026 DAYBUE net sales guidance increased to the range of US$480 to US$510 million.
"We are pleased to see an exceptional quarter for DAYBUE, with very strong sales volume growth reflecting the early success of [DAYBUE] STIX in the US," Neuren CEO Jon Pilcher said.
